Worldwide Clinical trials Drug Development Solutions
Mr Peck has a diverse background in operations, business development, project management and customer service gained over 18 years in the contract research industry. He has held senior management positions directing the full scope of clinical research operations including leadership of recruitment and patient qualification, clinical conduct and compliance, quality control, data transcription, pharmacy and laboratory services.
Prior to joining Worldwide Clinical Trials drug development solutions, Inc., Mr Peck was responsible for directing the multi-specialty operations and start-up activities of a 120-bed Clinical Pharmacology Unit at ICON Development Solutions in Omaha, Nebraska. He implemented a clinical trial management system for data collection and obtained ISO certification as the quality management system for the site.
Earlier in his career, Mr Peck worked for MDS Pharma Services in Lincoln, Nebraska where he directed and expanded the Phase I and IIa clinical site from 140 beds to 200 beds, and opened a participant screening facility in Omaha, Nebraska. While there he led a multi-disciplined staff in excess of 170 clinical associates, physicians and pharmacists. He chaired the Site Management Committee comprised of senior leaders from Bioanalytical, PK/Stats, Data Management and other support services. Mr Peck was responsible for the conduct and regulatory compliance of over 500 clinical trials including first in man, radiolabeled, dose escalation, bioequivalence and drug interaction studies, as well as the integration and expansion of clinical sites in New Jersey, Louisiana and Virginia. Mr Peck received his BS degree in Business Administration from Northern State University.
Stemedica Posts Alzheimer's Stem Cell Data — Drug Discovery & Development
Stemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer's disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant ..
New partnership brings more personalized cancer treatment to Philadelphia — Phys.Org
"Our participation in the WIN consortium means Jefferson cancer patients will have access to worldwide clinical trials on promising and individualized therapies," says Massimo Cristofanilli, M.D., Director of the Jefferson Breast Care Center. "It ..
Core Science FlexCore Joint Support, Veggie Caps 90 ea
Health and Beauty (AB)
Sambucol Sambucol Black Elderberry Immune - 4 Oz